JP2020516615A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516615A5
JP2020516615A5 JP2019554976A JP2019554976A JP2020516615A5 JP 2020516615 A5 JP2020516615 A5 JP 2020516615A5 JP 2019554976 A JP2019554976 A JP 2019554976A JP 2019554976 A JP2019554976 A JP 2019554976A JP 2020516615 A5 JP2020516615 A5 JP 2020516615A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
protein
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019554976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516615A (ja
JP7789303B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026447 external-priority patent/WO2018187682A1/en
Publication of JP2020516615A publication Critical patent/JP2020516615A/ja
Publication of JP2020516615A5 publication Critical patent/JP2020516615A5/ja
Priority to JP2023208379A priority Critical patent/JP2024037834A/ja
Application granted granted Critical
Publication of JP7789303B2 publication Critical patent/JP7789303B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019554976A 2017-04-07 2018-04-06 上皮バリア機能障害の治療のためのタンパク質 Active JP7789303B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023208379A JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US62/482,963 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US62/607,706 2017-12-19
US201762611334P 2017-12-28 2017-12-28
US62/611,334 2017-12-28
PCT/US2018/026447 WO2018187682A1 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023208379A Division JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Publications (3)

Publication Number Publication Date
JP2020516615A JP2020516615A (ja) 2020-06-11
JP2020516615A5 true JP2020516615A5 (enExample) 2021-05-13
JP7789303B2 JP7789303B2 (ja) 2025-12-22

Family

ID=63710147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554976A Active JP7789303B2 (ja) 2017-04-07 2018-04-06 上皮バリア機能障害の治療のためのタンパク質
JP2023208379A Pending JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023208379A Pending JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Country Status (12)

Country Link
US (3) US10251933B2 (enExample)
EP (1) EP3606542A4 (enExample)
JP (2) JP7789303B2 (enExample)
KR (2) KR20200003821A (enExample)
CN (1) CN110769844B (enExample)
AU (2) AU2018248324B2 (enExample)
CA (1) CA3059354A1 (enExample)
IL (1) IL269853A (enExample)
MX (2) MX393998B (enExample)
SG (1) SG11201909334TA (enExample)
TW (1) TWI797116B (enExample)
WO (1) WO2018187682A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909334TA (en) * 2017-04-07 2019-11-28 Second Genome Inc Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11505583B2 (en) 2018-04-06 2022-11-22 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
EP4017880A4 (en) * 2019-08-21 2023-10-11 Astrazeneca Collaboration Ventures, LLC USE OF BRAZIKUMAB TO TREAT CROHN'S DISEASE
EP4087859A4 (en) * 2020-01-10 2024-02-14 National Taipei University of Technology PEPTIDE INTERACTING WITH THE TOLL-LIKE RECEPTOR 2 AND COMPOSITION THEREOF
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用
EP4611774A2 (en) * 2022-11-04 2025-09-10 MiNK Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5552284A (en) 1991-03-29 1996-09-03 Genentech, Inc. Detection of interleukin-8 receptors by nudeic acid hybridization
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
DK2424885T3 (en) 2009-04-28 2016-06-06 Univ Vanderbilt Compositions and methods for the treatment of disorders involving epitelcelleapoptose
GB201117313D0 (en) * 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
SG11201909334TA (en) 2017-04-07 2019-11-28 Second Genome Inc Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11174293B2 (en) 2017-06-02 2021-11-16 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Similar Documents

Publication Publication Date Title
AU2020336649B2 (en) Akkermansia muciniphila EB-AMDK19 strainand use thereof
KR102140910B1 (ko) Chp(사이클로-히스프로)를 포함하는 섬유증의 예방, 개선 또는 치료용 조성물
US20240066095A1 (en) Proteins for the treatment of epithelial barrier function disorders
US12168677B2 (en) Proteins for the treatment of epithelial barrier function disorders
WO2015007216A1 (zh) 多肽、编码该多肽的dna分子、载体、制备方法及应用
CN102973554B (zh) 土木香内酯在制备防治溃疡性结肠炎的药物或食品中的应用
KR20240026882A (ko) 락토바실러스 뮤코세 및 수용성 식이섬유의 조합물을 사용한 방법 및 조성물
CN113286604A (zh) 治疗炎症性疾病的蛋白质
JP2021514354A5 (enExample)
US12186364B2 (en) Proteins for the treatment of epithelial barrier function disorders
CN113274384B (zh) 驴食草酚在制备防治溃疡性结肠炎的药物中的应用及其药物
US11911409B2 (en) Pharmaceutical composition for treatment and prevention of chronic disease
WO2013004069A1 (zh) 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用
JP7469812B2 (ja) 抗微生物特性を有する化合物
CN116492325A (zh) 以衣康酸为起点抑制Tet靶点蛋白的药物开发
JP2009263307A (ja) 炎症性腸疾患の予防・治療剤
EP3538132A1 (en) Rectal insulin for treatment of inflammatory bowel diseases
CN107951898B (zh) mir-146a-5p在治疗肠易激综合征内脏高敏感性中的应用
CN116350748A (zh) Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用
CN115429870A (zh) 白介素40在防治中性粒细胞减少症中的应用
Warner et al. Alcohol-induced liver injury is attenuated by human beta defensin in experimental ALD via improvements in the gut-liver axis
CN120661670B (zh) Clic5基因在制备预防和/或治疗肠道炎症的药物中的应用
JP2020132575A (ja) 血管新生促進剤
CN105079012A (zh) 天麻素在制备防治溃疡性结肠炎的药物或食品中的应用
CN111281866A (zh) 一种预防或治疗溃疡性结肠炎的中药化学制剂